Cargando…

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit

OBJECTIVE: To explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding nephrotoxicity. METHODS: The medical records of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Bo, Xiong, Wenyi, Bai, Ke, Dang, Hongxing, Li, Jing, Xu, Feng, Fu, Yue-qiang, Liu, Chengjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279905/
https://www.ncbi.nlm.nih.gov/pubmed/35844752
http://dx.doi.org/10.3389/fped.2022.867712
_version_ 1784746509137346560
author Zhou, Bo
Xiong, Wenyi
Bai, Ke
Dang, Hongxing
Li, Jing
Xu, Feng
Fu, Yue-qiang
Liu, Chengjun
author_facet Zhou, Bo
Xiong, Wenyi
Bai, Ke
Dang, Hongxing
Li, Jing
Xu, Feng
Fu, Yue-qiang
Liu, Chengjun
author_sort Zhou, Bo
collection PubMed
description OBJECTIVE: To explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding nephrotoxicity. METHODS: The medical records of hospitalized children with severe infection treated with vancomycin in the PICU of a tertiary pediatric hospital from September 2018 to January 2021 were retrospectively collected. Univariate analysis was used to assess the correlation between vancomycin pharmacokinetic/pharmacodynamic parameters and therapeutic efficacy or vancomycin-related nephrotoxicity. Binary logistic regression was used to analyze the risk factors for vancomycin-related nephrotoxicity. The vancomycin area under the concentration-time curve over 24 h (AUC(0–24)) threshold was determined by receiver operating characteristic (ROC) curve analysis. RESULTS: One hundred and 10 patients were included in this study. Seventy-six patients (69.1%) exhibited clinically effective response, while the rest exhibited clinically ineffective response. There were no significant differences in APACHE II score, steady-state trough concentration, peak concentration or AUC(0–24) of vancomycin between the effective and ineffective groups. Among the 110 patients, vancomycin-related nephrotoxicity occurred in 15 patients (13.6%). Multivariate analysis showed that vancomycin treatment duration, trough concentration, and AUC(0–24) were risk factors for vancomycin-related nephrotoxicity. The ROC curve indicated that AUC(0–24) < 537.18 mg.h/L was a suitable cutoff point for predicting vancomycin-related nephrotoxicity. CONCLUSION: No significant correlations were found between the trough concentration or AUC(0–24) of vancomycin and therapeutic efficacy when the daily dose of vancomycin was approximately 40 mg/kg d, while the trough concentration and AUC(0–24) were both closely related to vancomycin-related nephrotoxicity. The combination of AUC(0–24) and trough concentration for therapeutic drug monitoring may reduce the risk of nephrotoxicity.
format Online
Article
Text
id pubmed-9279905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92799052022-07-15 Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit Zhou, Bo Xiong, Wenyi Bai, Ke Dang, Hongxing Li, Jing Xu, Feng Fu, Yue-qiang Liu, Chengjun Front Pediatr Pediatrics OBJECTIVE: To explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding nephrotoxicity. METHODS: The medical records of hospitalized children with severe infection treated with vancomycin in the PICU of a tertiary pediatric hospital from September 2018 to January 2021 were retrospectively collected. Univariate analysis was used to assess the correlation between vancomycin pharmacokinetic/pharmacodynamic parameters and therapeutic efficacy or vancomycin-related nephrotoxicity. Binary logistic regression was used to analyze the risk factors for vancomycin-related nephrotoxicity. The vancomycin area under the concentration-time curve over 24 h (AUC(0–24)) threshold was determined by receiver operating characteristic (ROC) curve analysis. RESULTS: One hundred and 10 patients were included in this study. Seventy-six patients (69.1%) exhibited clinically effective response, while the rest exhibited clinically ineffective response. There were no significant differences in APACHE II score, steady-state trough concentration, peak concentration or AUC(0–24) of vancomycin between the effective and ineffective groups. Among the 110 patients, vancomycin-related nephrotoxicity occurred in 15 patients (13.6%). Multivariate analysis showed that vancomycin treatment duration, trough concentration, and AUC(0–24) were risk factors for vancomycin-related nephrotoxicity. The ROC curve indicated that AUC(0–24) < 537.18 mg.h/L was a suitable cutoff point for predicting vancomycin-related nephrotoxicity. CONCLUSION: No significant correlations were found between the trough concentration or AUC(0–24) of vancomycin and therapeutic efficacy when the daily dose of vancomycin was approximately 40 mg/kg d, while the trough concentration and AUC(0–24) were both closely related to vancomycin-related nephrotoxicity. The combination of AUC(0–24) and trough concentration for therapeutic drug monitoring may reduce the risk of nephrotoxicity. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9279905/ /pubmed/35844752 http://dx.doi.org/10.3389/fped.2022.867712 Text en Copyright © 2022 Zhou, Xiong, Bai, Dang, Li, Xu, Fu and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Zhou, Bo
Xiong, Wenyi
Bai, Ke
Dang, Hongxing
Li, Jing
Xu, Feng
Fu, Yue-qiang
Liu, Chengjun
Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
title Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
title_full Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
title_fullStr Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
title_full_unstemmed Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
title_short Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
title_sort clinical application value of pharmacokinetic parameters of vancomycin in children treated in the pediatric intensive care unit
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279905/
https://www.ncbi.nlm.nih.gov/pubmed/35844752
http://dx.doi.org/10.3389/fped.2022.867712
work_keys_str_mv AT zhoubo clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT xiongwenyi clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT baike clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT danghongxing clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT lijing clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT xufeng clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT fuyueqiang clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit
AT liuchengjun clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit